Valois achieved full-year income of €30.5m ($48m), up 28 per cent on its 2006 earnings, while annual revenue hit €345.6m, 11 per cent higher than that recorded the previous year. The French firm said that sales were strong across both its pharmaceutical and beauty divisions, particularly following the launch of several new products that incorporate its dispensing technologies. In addition, the company also highlighted a number of its own product launches that helped boost the year's results including the Evolution and Custom Packages for its beauty and home care division. Valois also reported that its new range of chlorofluorocarbon (CFC)-free metering valves for the delivery of pulmonary drug products made a significant contribution to its coffers. The impending US ban on CFC-based albuterol inhalers, which comes into effect on December 31, is likely to see demand for technologies like Valois' metering valves continue to increase as drugmakers seek to target the lucrative US market. A recent study by Decision Resources suggested that the US albuterol CFC sector is worth nearly $400m a year. In addition, Valois' 2007 operations had a distinctly international flavour, with sales outside France providing around 58 per cent of its total turnover. The firm reported that, while revenues derived from the European Union and North America remained strong, emerging markets like South America and Asia had made a significant contribution. Recent launches presented at LuxePack The company recently showcased its first pump designed specifically for the contours of the Eye and Lip areas at Luxe Pack New York. Evolux Eyes and Lips offers a micro-dose with maximum precision, according to the company, which also highlights that the completely metal free system will respect even the most fragile formulas. The pump was showcased at the packaging show earlier this month but will be available from the end of this year.